Lanstead United Kingdom Announcement

Lanstead provides £5m to AIM Quoted ImmuPharma to support the pivotal Phase III clinical trial of Lupuzor™

October 4, 2017 / POSTED BY / CATEGORY: Announcements

Global investment firm Lanstead is pleased to announce that its Sharing Agreement with AIM quoted, specialist drug discovery and development company, ImmuPharma plc (AIM: IMM) (“ImmuPharma” or the “Company”) has been successfully completed, with ImmuPharma having received over £5 million from Lanstead, £600,000 more than was originally subscribed, through the…

READ MORE

Lanstead Australia Announcement

Lanstead invests A$10 million in support of Rett syndrome Phase 3 trial

June 29, 2017 / POSTED BY / CATEGORY: Announcements

Global investment firm Lanstead has today announced its A$10 million investment in Australian biotechnology firm Neuren Pharmaceuticals Ltd (“Neuren”) (ASX: NEU) ahead of an upcoming Rett syndrome Phase 3 trial. Neuren is developing novel new therapies for brain injuries, neurodevelopmental and neurodegenerative disorders. It currently has a clinical stage molecule,…

READ MORE


Lanstead Australia Announcement

Lanstead invests A$4 million to support SmartTrans’ e-commerce and SmartPay

December 28, 2016 / POSTED BY / CATEGORY: Announcements

Global investment firm Lanstead has today announced its A$4 million investment in SmartTrans Holdings Limited (“SmartTrans”) (ASX: SMA) to fund the expansion of their e-commerce platforms and facilitate the rollout of their SmartPay payments platform in Australia and China. SmartTrans recently announced a Memorandum of Understanding (MOU) with Shanghai Stock…

READ MORE

Lanstead United Kingdom Announcement

Lanstead Invests £4.4 million in ImmuPharma PLC in support of Lupuzora™ phase 3 trial

February 5, 2016 / POSTED BY / CATEGORY: Announcements

Global investment firm Lanstead has today announced its £4.4 million investment in AIM quoted, specialist drug discovery and development company, ImmuPharma plc (AIM: IMM) as the business looks to commence its pivotal Phase III clinical trial of Lupuzor™, the Company’s lead programme for the potential breakthrough compound for Lupus, the…

READ MORE